Company: AZN
Filing Date: 2025-04-04
Form Type: 6-K
Source: 0001654954-25-003896
Chunk: 7

Company: ASTRAZENECA PLC
Filing Date: 2025-04-04
Form: 6-K
Chunk 7
---
 unresectable non-small-cell lung cancer. Curr Oncol . 2019;26(1):37-42.

10. AstraZeneca PLC. Investor Relations Epidemiology Spreadsheet. Available at: https://www.astrazeneca.com/investor-relations.html . Accessed April 2025.

11. Sethi S, et al. Incidental Nodule Management - Should There Be a Formal Process? J Thorac Dis . 2016:8(Suppl 6);S494-S497.

12. LUNGevity Foundation. Screening and Early Detection. Available at: https://lungevity.org/for-patients-caregivers/lung-cancer-101/screening-early-detection . Accessed April 2025.

#### Adrian Kemp

#### Company Secretary

#### AstraZeneca PLC
<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AstraZeneca 
 PLC         |

Date: 04 April 2025

| By: /s/           
 Adrian Kemp       |
| Name:             
 Adrian Kemp       |
| Title:            
 Company Secretary |